|
|
|
시장보고서
Monoclonal Antibody Based Products
|
Abstract
This report analyzes the worldwide markets for Monoclonal Antibody Based
Products in Millions of US$. The major product segments and application areas
analyzed are Therapeutics, and Diagnostics, especially for cancer. The report
provides separate comprehensive analytics for the US, Canada, Japan, Europe,
and Rest of world. Annual forecasts are provided for each region for the
period of 2003 through 2015. The report profiles 123 companies including many
key and niche players worldwide such as Amgen, Inc., BD Biosciences, Biogen
Idec, CMC ICOS Biologics, Inc., Dendreon Corporation, Eli Lilly and Company,
Genentech, Inc., Human Genome Sciences, Inc., Immunomedics, Johnson & Johnson,
Centocor, Ortho Biotech Products, L.P., Medarex Inc, Medlmmune Inc, PDL
BioPharma, Schering-Plough Corporation, Strategic Diagnostics Inc., and Wyeth
Pharmaceuticals. Market data and analytics are derived from primary and
secondary research. Company profiles are mostly extracted from URL research
and reported select online sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Therapeutics
- Cancer
- Other Therapeutic Mabs
- Diagnostics
II. EXECUTIVE SUMMARY
1. Industry Overview
- World MAb-Based Products Market: A Profile
- MAb Market - Set for Significant Growth
- Therapeutic mAb Market - Principal Driving Force
- Development of New MAbs on a Fast Track
- Genomics Research Leads Way to New Monoclonal Antibodies
- Bright Outlook for MAbs
- Current and Future Analysis
- Regional Perspective
- Product Segment Perspective
- Competitive Scenario
- Intensifying Consolidation Activity
- Table 1: Major Acquisitions of Antibody-Focused Companies (2005-2007)
- Table 2: Leading Players in the Worldwide Monoclonal Antibody Therapy
Market (2005): Percentage Breakdown of Sales for Genentech/Roche, J &
J/Schering Plough, Abbott Laboratories, MedImmune, ImClone/BMS, and Eli Lilly
(includes corresponding Graph/Chart)
- Table 3: Leading Drugs in the Global Therapeutic Monoclonal Antibodies
Market (2006): Percentage Breakdown of Dollar Sales for Remicade, Rituxan,
Herceptin, Avastin, Humira, Erbitux, Synagis, Xolair and Others (includes
corresponding Graph/Chart)
- Table 4: Monoclonal Antibody Based Products Market (2004): Percentage
Breakdown of Leading Manufacturers by Sales for Genentech, Johnson &
Johnson, Roche, Abbott, MedImmune, Schering Plough, Eli Lilly, and Others
(includes corresponding Graph/Chart)
- Table 5: Monoclonal Antibody Based Products Market (2004): Percentage
Breakdown of Leading Drugs by Sales for Remicade, Rituxan, Herceptin, Synagis,
Humira, Avastin, ReoPro, Erbitux, Xolair, and Others (includes corresponding
Graph/Chart)
- Table 6: Leading Products in the Global Oncology Monoclonal Antibodies
Market (2008E): Percentage Share Breakdown of Sales for Avastin, Herceptin,
Rituxan, Erbitux, and Others (includes corresponding Graph/Chart)
- Table 7: Leading Products in the Global Antibody-Based Anti-Inflammatory
Market (2006): Percentage Share Breakdown of Revenues for Enbrel, Remicade,
Humira, and Others (includes corresponding Graph/Chart)
- Therapeutic Antibodies in the Market
- Drug Developers Trying to Break the Shackles
- Rituximab Vs. Epratuzumab
- A Revolution Not too Far
- Milestones in Development of MAbs
- Focus on Unmet Medical Needs in the Emerging Markets
2. Industry Analysis
- Evolution of Monoclonal Antibodies - A Historical Journey
- Trends and Issues
- Shift Towards Humanized and Fully Human Antibodies
- Ageing Baby Boomers Spur MAbs Growth
- Non-Existent Generic Competition Favors MAb Market
- Partnerships and Collaborations Spark Increase in Profit Margins
- Pharma Majors & CMOs Augment Investment in Mab Production
- Rising Number of MAbs Under Clinical Trials
- Select Clinical Trials for Monoclonal Antibodies
- Major Monoclonal Antibodies in Phase III Trials Across the World
- High Costs Impede MAbs Penetration
- Opportunities in Technology Development
- Advancements & Challenges in Antibody Production Processes
- Increasing Demand for Protein A in Mab Manufacturing
- FCA- A Major Cause for Discomfort in Mice
- Innovations to Drive Growth in Anti-Ovarian Cancer Drugs Market
- Rising Incidence of NHL to Drive Monoclonal Antibody Drug Market
3. Product Overview
- Immune System: Natural Defenders
- Human Antibodies
- Antibodies Offer Natural Immunity
- Induction of The Immune Process
- Mechanism of Action
- Polyclonal and Monoclonal Antibodies
- Production of Monoclonal Antibodies
- Traditional Methods
- The Hybridoma Technology
- Separation and Purification of Monoclonals
- Factors Impacting Production of MAbs
- Types of Monoclonal Antibodies
- Table 8: Worldwide MAb Market by Product Type (2008): Percentage Share
Breakdown for Chimeric, Humanized, Human and Murine (includes corresponding
Graph/Chart)
- Murine Monoclonal Antibodies
- Humanized Antibodies/ CDR Grafted Antibodies
- Murine Vs Human Monoclonal Antibodies
- Chimeric Antibodies: Show Lesser Antigenicity
- Fully Human Antibodies
- Bispecific Antibodies
- Certain Limitations Do Exist
- Advantages of MAbs
- Advantages and Limitations of MAb Technologies
4. Diagnostic Applications of Monoclonal Antibodies
- Monoclonal Antibody Based Diagnostics
- Immunodiagnostics
- Monoclonals Used as Targeting Agents
- Radio labeled Monoclonal Antibodies for Diagnostic Imaging
- The Pros and Cons of MAb-Based Immunoconjugates
- Cytogen: The First to Introduce A Monoclonal Antibody-based Cancer Agent
- NeoProbe' s Radioimmunogzuided Surgery
- Cancer
- A Historical Overview
- Initial Hiccups
- Tumor Markers
5. Monoclonal Antibody-Based Therapeutics
- Evolution of Therapeutic Antibody Products
- Advantages of Therapeutic Monoclonal Antibodies
- Current Scenario in Monoclonal Antibody Therapeutics Market
- Table 9: Monoclonal Antibody Market by Therapy Area (2004 & 2010):
Percentage Breakdown by Sales for Oncology, Arthritis, Immune &
Inflammatory Disorders, Infectious Diseases, Cardiovascular, Respiratory,
Ophthalmology, and CNS (includes corresponding Graph/Chart)
- Cancer Therapeutics
- Monoclonal Antibodies Offer Hope Against Cancer
- Monoclonal Antibodies Approved For Cancer Treatment in the World
- Monoclonal Antibody Cancer Therapies Under Development
- Antibody Therapies for Cancer
- Cancer: A Serious Issue and Plaguing Illness Worldwide
- Breast Cancer: The Most Common Form of Cancer in American Women
- Breast Cancer - Treatment Options
- Monoclonal Antibodies Against NHL
- Monoclonal Antibodies Against Ovarian Cancer
- MAb Immunotherapy - Effective for Residual Ovarian Cancer
- Melanoma
- Immunologic Effector Functions
- Colorectal Cancer: Rising Incidence
- Panorex: The First Cancer Therapeutic in the Market
- Myeloid Leukemia
6. Other Therapeutic Monoclonal Antibodies
- Therapeutic Monoclonal Antibody Drugs and Applications
- MAbs used in Clinical Field
- Inflammation Therapeutics
- Inflammation
- Asthma: A Chronic Affliction
- Autoimmune Diseases
- What Goes Wrong
- Intervention Better Than Prevention
- Some Autoimmune Diseases
- Multiple Sclerosis
- Crohn' s Disease
- Rheumatoid Arthritis
- Organ Transplantation
- Biology of Transplantation
- Types of Transplants
- Autografts
- Syngeneic Transplants
- Allografts
- Xenografts
- Follow-up Treatment
- Products to Counter Rejection
- OKT3: A Monoclonal Already in the Market
- Infectious Diseases
- Sepsis
- A Rapid Process
- Gram Negative Bacteria are the Causative Agents
- A Retrospect
- Monoclonal Antibodies and Septic Shock
- HIV/AIDS
- What is AIDS?
- Global Statistics
- HIV/AIDS Testing
- Monoclonal Antibodies and HIV
- Cardiovascular
- Cardiovascular Diseases are Fatal
- Treatment Options
- Causes of Cardiovascular Diseases
- ReoPro
7. Regulation Impacting The Industry
- Regulations in the U.S
- Approval: A Laborious Process
- Clinical Trials
- Orphan Drug Status
8. Research and Development Activities
- Rituxan and Herceptin from Genentech
- FuCell hybridomas
- Test-tube MAbs/ Phase Display Library
- Rituxan for Cancer Treatment
- GenMAb Develops Fully Human Antibodies
- Protein Design Labs Licenses Trioma
- Protein Design Labs' Innovative Technology
9. Product Launches and Developments
- Amgen Introduces Vectibix
- Trevigen Introduces Mouse Monoclonal Antibody
- UCB Receives FDA Approval for Cimzia(r)
- GSK' s Tykerb Receives FDA Approval
- Dr. Reddy' s Introduces Reditux(tm)
- Morphotek Receives Orphan Drug Status for MORAb - 009 mAb
- Biocon Introduces BIOMab Monoclonal Antibody
- Biotest AG and AERES Biomedical Develop BT- 062
- Genentech Launches Avastin
- Biotest Unveils Intratect(r)
- Genentech Introduces Xolair
- Genentech Unveils Raptiva
- Corixa Presents BEXXAR
- IGEN Launches Monoclonal Antibody Therapies
- MAb Against Pseudomonas Aeruginosa
- Wyeth Introduces Mylotarg
10. Recent Industry Activity
- EUSA Pharma to Take Over Cytogen
- AVANIR Inks a Definitive Agreement to Divest Anthrax Antibodies
- Access Pharmaceuticals Acquires Somanta Pharmaceuticals
- Daiichi Sankyo to Take Over U3 Pharma
- IMUC Completes Molecular Antibody Technology Acquisition
- Callisto Merger Corporation Merges with Celldex Therapeutics
- Genmab Enters into Antibody Research Collaboration with Pepscan
- BTI Enters into an Agreement with Raven
- Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104
- Eusa Sells Antibody Research Business
- CG Therapeutics and UoW Agree for Joint Monoclonal Antibody Program
- Raven and CMC ICOS Collaborate to Advance RAV18
- SDI to Develop mAbs for SAIC-F and NCI
- HGS Reacquires Rights for TRAIL Receptor Antibodies
- CAT Grants Exclusive Worldwide License of CAT-213 to iCo
- Morphotek and HMI in Licensing Agreement
- Amgen Enters into Licensing Agreement with Kyowa Hakko
- Dyax and Sanofi-Aventis Sign Agreements
- HGS Enters into Antibody Collaboration Agreement with Xencor
- CSL Limited Inks a Collaboration Agreement with Celltrion
- Eisai Acquires Morphotek
- Astellas US Holding Takes Over Agensys
- Astrazeneca Creates New Integrated Business Unit - Medimmune
- Genentech Acquires Tanox
- Biotest Acquires Assets of Nabi Biologics
- CMC Acquires ICOS Biologics Operation
- Roche Takes Over THP
- GTC and LFB Commence CD20 Monoclonal Antibody Development
- Regeneron Grants a Non-Exclusive License to AstraZeneca
- OncoMed Enters into Monoclonal Antibody Deal with GSK
- BioArctic and Eisai Announce Licensing Agreement
- MediGene Collaborates with Celltrion
- Amgen Inks Collaboration and License Pact with Daiichi Sankyo
- CMC Biopharmaceuticals Inks Agreement with Morphotek
- CMC Biopharmaceuticals Inks Agreement with Biotest
- Eli Lilly Collaborates with MacroGenics
- Genentech Inks Global Licensing Agreement with Seattle Genetics
- VaxGen to Merge with Raven Biotechnologies
- Abeome Enters into Distribution Agreement with Millipore
- Compugen Forays into Monoclonal Antibody Business
- MilleGen and LFB Enter into Partnership Agreement
- Favrille Acquires Diversa' s Anti-CD20 Monoclonal Antibodies
- Kirin Inks Licensing Agreement with Astellas Pharma
- Viropro in Partnership with NRC-BRI
- Merck Acquires Abmaxis
- Micromet Merges with CancerVax
- Tanabe & Janssen Team Up to Develop Anti-TNF Alpha Monoclonal Antibody
- Intercell Enters into Strategic Alliance with Kirin
- Xencor Extends R&D Collaboration with Roche
- MedImmune Inks Licensing Agreement with Japan Tobacco
- Immunomedics Enters into an Agreement with UCB for Epratuzumab
- Akorn and Serum Institute Enter into Development and Distribution Agreement
- FDA Clears IND for CYT-500 Monoclonal Antibody from Cytogen
- LSP Acquires Global License for Monoclonal Antibodies from Ludwig Institute
- Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal
Antibody Drug Candidates
- EU Grants Orphan Drug Designation to GPC' s Anticancer Monoclonal Antibody
- Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for
Cancer Treatment
- Amgen Takes Over Abgenix
- Celera and Medarex in Strategic Alliance for Developing Human Monoclonal
Antibody Therapeutics
- UCB Collaborates with Immunomedics
- Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business
- Roche Licenses Rabbit Monoclonal Antibody Technology from Epitomics
- BioGenex Receives FDA Pre-Market Approval for InSite(tm) Monoclonal
Antibody
- Upstate Bags Marketing Rights for Anti-ZAP-70 Monoclonal Antibody
- XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal
Antibodies
- HGS Bags Two-Phase Contract for ABthrax(tm) Mab from the US Government
- Medarex and PharmAthene Receive Funding for Development of Valortim(tm)
- UCB Collaborates with Millenium
- MorphoSys Acquires Two Antibody Technology Companies
- Tanabe Seiyaku and Remicade Sign Addendum
- Abgenix Receives Royalty from Human Genome
- Amgen Acquires Tularik
- Sunesis Pharmaceuticals Collaborates with Biogen Idec
- H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics
- EMBL and Abnova Inks Collaboration Agreement
- AstraZeneca and CAT in Five-Year Strategic Alliance for Monoclonal
Antibody Research
- UCB Acquires Celltech
- ImmunoGen Signs Licensing Agreement with Biogen
- Lonza Inks MAbs Manufacturing and Supply Agreement with NovImmune
- Avanir and Peregrine Sign License Agreement
- BioVest Concludes Agreement with Bioventix
- Roche to Set Up Two Manufacturing Facilities in Switzerland
- XTL Biopharm Bags European patent for Human Monoclonal Anti Body
- MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials
- Health Canada Approves HUMIRA
11. Industry Activity in the Recent Past (2000-2003)
- CAT Signs Licensing Agreement with Micromet
- CAT Enters into Agreement with Genzyme
- Medarex and Avlon Enter into Agreement
- Micromet, Enzon and CAT Sign Cross-License Agreement
- Xerion and CAT Enter into Agreement
- Genetastix and Nissho Enter into Agreement
- InNexus and Corixa Enter into Agreement
- Abbott Collaborates with LigoCyte
- CAT Acquires Drug Royalty Corporation
- CAT and Amrad Join Hands for Research
- IDEC' s Receives FDA Approval for Zevalin
- Medarex Enters into Research Alliance with Seattle Genetics
- Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody
- Eos, Medarex and Biosite in Alliance for Cancer Treatment
- Imgenex forms Alliance with GMO
- CAT and Elan Enter into Strategic Alliance
- Bioinvent International Enters into Agreement with Novo Nordisk for Drug
Discovery Research
- Epicyte and Dow Chemical Enter into Agreement
- Rockland Announces the Completion of Laboratory Expansion
- Roche' s MAbThera Receives Approval in Japan
- Aviva Launches Manufacturing and Marketing Operations
- ICOS and Seattle Enters into Joint Development and Manufacturing Agreement
- Medarex and Corixa Team-up to Develop Human Monoclonal Antibodies
- Taisho Enters into Research Alliance with IDEC
- PDL Signs Agreement with InterMune
- ProMetic Signs Agreement with Integrated Protein
- Medarex Signs Agreement with ZynloGenetics
- CAT Joins Hands with GD. Searle
- Medarex and MedImmune Enter into Antibody Research Agreement
- Lonza Signs Agreement with ImClone Systems
- MedImmune and Alkermes Enter into Agreement
- GTC and Abgenix Enter into Production Agreement
- Genzyme Transgenics Expands Agreement with Centocor
- PDL and InterMune Enter into an Agreement
12. Focus on Select Global Players
- Amgen, Inc. (US)
- BD Biosciences (US)
- Biogen Idec Inc (US)
- Biotest AG (Germany)
- CMC ICOS Biologics, Inc.
- Dendreon Corporation (US)
- Elan Corporations Plc (Ireland)
- Eli Lilly and Company (US)
- Genentech, Inc. (USA)
- Human Genome Sciences, Inc. (US)
- Immunomedics (US)
- Johnson & Johnson (US)
- Centocor (US)
- Ortho Biotech Products, L.P. (US)
- Medarex, Inc. (US)
- MedImmune, Inc. (US)
- PDL BioPharma (US)
- Schering-Plough Corporation (US)
- Strategic Diagnostics Inc (US)
- UCB Group (Belgium)
- Wyeth Pharmaceuticals (US)
13. Global Market Perspective
- Table 10: World Recent Past, Current & Future Market Analysis for
Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan,
Europe, and Rest of World Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 11: World Long-term Projections for Monoclonal Antibody Based
Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart)
- Table 12: World 10-Year Perspective for Monoclonal Antibody Based Products
by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart)
- Table 13: World Recent Past, Current & Future Market Analysis for
Therapeutic Monoclonal Antibody Based Products by Geographic Region - US,
Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2010 (includes
corresponding Graph/Chart)
- Table 14: World Long-term Projections for Therapeutic Monoclonal Antibody
Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of
World Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 15: World 10-Year Perspective for Monoclonal Antibody Based Products
by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart)
- Table 16: World Long-term Projections for Therapeutic Monoclonal Antibody
Based Products by Segment - Cancer and Other Therapeutics Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010
(includes corresponding Graph/Chart)
- Table 17: World Long-term Projections for Therapeutic Monoclonal Antibody
Based Products by Segment - Cancer and Other Therapeutics Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart)
- Table 18: World 10-Year Perspective for Therapeutic Monoclonal Antibody
Based Products by Segments - Percentage Breakdown of Dollar Sales for Cancer
and Other Therapeutics Markets for Years 2003, 2008 & 2012
- Table 19: World Recent Past, Current & Future Market Analysis for
Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region -
US, Canada, Japan, Europe, and Rest of World Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes
corresponding Graph/Chart)
- Table 20: World Long-term Projections for Cancer Therapeutic Monoclonal
Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and
Rest of World Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 21: World 10-Year Perspective for Cancer Therapeutic Monoclonal
Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart)
- Table 22: World Recent Past, Current & Future Market Analysis for
Other Therapeutic Monoclonal Antibody Based Products by Geographic Region -
US, Canada, Japan, Europe, and Rest of World Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes
corresponding Graph/Chart)
- Table 23: World Long-term Projections for Other (*) Therapeutic Monoclonal
Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and
Rest of World Independently Analyzed with Annual Sales Figures in US$ Million
for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 24: World 10-Year Perspective for Other Therapeutic Monoclonal
Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart)
- Table 25: World Recent Past, Current & Future Market Analysis for
Diagnostic Monoclonal Antibody Based Products by Geographic Region - US,
Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2010 (includes
corresponding Graph/Chart)
- Table 26: World Long-term Projections for Diagnostic Monoclonal Antibody
Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of
World Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 27: World 10-Year Perspective for Diagnostic Monoclonal Antibody
Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 &
2012 (includes corresponding Graph/Chart)
III. MARKET
1. The Untied States
- A. Market Analysis
- Global Hub of MAbs
- Approved Therapeutic Antibodies in the US (As of 2007)
- Therapeutic Monoclonal Antibodies Market - An Overview
- New Heights f or US Cancer Therapeutics
- Competitive Landscape
- Leading Products
- Table 28: Leading Products in the US Therapeutic Monoclonal Antibodies
Market (2007): Percentage Breakdown of Revenues for Remicade, Avastin,
Rituxan, Herceptin, Synagis, Lucentis, Erbitux, and Others (includes
corresponding Graph/Chart)
- Table 29: Leading Players in the US Therapeutic Monoclonal Antibodies
Market (2007): Percentage Share Breakdown of Revenues for Genentech Inc,
Centocor, MedImmune, Bristol Meyer' s Squibb, Amgen, Hoffman-La Roche, and
Others (includes corresponding Graph/Chart)
- Focus on Key Players
- Amgen, Inc.
- BD Biosciences
- Biogen Idec.
- CMC ICOS Biologics, Inc.
- Dendreon Corporation
- Eli Lilly and Company
- Genentech, Inc.
- Human Genome Sciences
- Immunomedics
- Johnson & Johnson
- Centocor
- Ortho Biotech Products, L.P.
- Medarex, Inc.
- MedImmune, Inc
- PDL BioPharma
- Schering-Plough Corporation
- Strategic Diagnostics Inc
- Wyeth Pharmaceuticals
- Product launches
- Strategic Developments
- B. Market Analytics
- Table 30: US Recent Past, Current & Future Analysis for Monoclonal
Antibody Based Products by Segment - Therapeutics (Cancer and Others), and
Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 31: US Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 32: US 10-Year Perspective for Monoclonal Antibody Based Products
by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer
and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
2. Canada
- A. Market Analysis
- B. Market Analytics
- Table 33: Canadian Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and
Others), and Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010 (includes corresponding
Graph/Chart)
- Table 34: Canadian Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 35: Canadian 10-Year Perspective for Monoclonal Antibody Based
Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics
(Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart)
3. Japan
- A. Market Analysis
- B. Market Analytics
- Table 36: Japanese Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and
Others), and Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010, (includes corresponding
Graph/Chart)
- Table 37: Japanese Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 38: Japanese 10-Year Perspective for Monoclonal Antibody Based
Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics
(Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart)
4. Europe
- A. Market Analysis
- Biotechnology and Pharmacy Research
- Monoclonal Antibody Based Products Market in Europe
- European Therapeutic MAbs Market - An Overview
- Approved Therapeutic Antibodies in Europe as of 2004
- Need to Reduce Complexities, Time & Cost of mAb Development
- Information Dissemination - Critical for Enhancing mAb Sales
- Monoclonal Antibody Immunotherapy for NHL
- MabThera - A Dominant MAb Drug in Europe
- Emerging Radioimmunotherapy Products
- Challenges for New Drug Development
- B. Market Analytics
- Table 39: European Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Geographic Region - France, Germany,
Italy, UK & Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2010 (includes
corresponding Graph/Chart)
- Table 40: European Long-term Projections for Monoclonal Antibody Based
Products by Geographic Region - France, Germany, Italy, UK & Rest of
Europe Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 41: European Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and
Others), and Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010 (includes corresponding
Graph/Chart)
- Table 42: European Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 43: European 10-Year Perspective for Monoclonal Antibody Based
Products by Geographic Region -Percentage Breakdown of Dollar Sales for
France, Germany, Italy, The UK, and Rest of Europe for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart)
- Table 44: European 10-Year Perspective for Monoclonal Antibody Based
Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics
(Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart)
4a. France
- A. Market Analysis
- B. Market Analytics
- Table 45: French Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and
Others), and Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010 (includes corresponding
Graph/Chart)
- Table 46: French Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
(Cancer and Others) Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart)
- Table 47: French 10-Year Perspective for Monoclonal Antibody Based
Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics
(Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart)
4b. Germany
- A. Market Analysis
- Biotest AG- A Key Player
- Product Launches
- Strategic Developments
- B. Market Analytics
- Table 48: German Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and
Others), and Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010 (includes corresponding
Graph/Chart)
- Table 49: German Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 50: German 10-Year Perspective for Monoclonal Antibody Based
Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics
(Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart)
4c. Italy
- Market Analysis
- Table 51: Italian Recent Past, Current & Future Analysis for
Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and
Others), and Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2010 (includes corresponding
Graph/Chart)
- Table 52: Italian Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 53: Italian 10-Year Perspective for Monoclonal Antibody Based
Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics
(Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012
(includes corresponding Graph/Chart)
4d. The United Kingdom
- A. Market Analysis
- Monoclonal Antibodies Market - An Overview
- Strategic Developments
- Product Launches
- B. Market Analytics
- Table 54: UK Recent Past, Current & Future Analysis for Monoclonal
Antibody Based Products by Segment - Therapeutics (Cancer and Others), and
Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
- Table 55: UK Long-term Projections for Monoclonal Antibody Based
Products by Segment - Therapeutics (Cancer and Others), and Diagnostics
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 56: UK 10-Year Perspective for Monoclonal Antibody Based Products
by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer
and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
4e. Rest of Europe
- A. Market Analysis
- Key Players
- Elan Corporations Plc (Ireland)
- UCB Group (Belgium)
- Strategic Developments
- B. Market Analytics
- Table 57: Rest of Europe Market for Monoclonal Antibody Based Products -
Recent Past, Current & Future Analysis by Product Segment for
Therapeutics (Cancer and Others), and Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2003 through
2010 (includes corresponding Graph/Chart)
- Table 58: Rest of Europe Long-term Projections for Monoclonal Antibody
Based Products by Segment - Therapeutics (Cancer and Others), and
Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 59: Rest of Europe 10-Year Perspective for Monoclonal Antibody
Based Products by Segment - Percentage Breakdown of Dollar Sales for
Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008
& 2012 (includes corresponding Graph/Chart)
5. Rest of World
- A. Market Analysis
- Australia
- India
- Strategic Developments
- B. Market Analytics
- Table 60: Rest of World Market for Monoclonal Antibody Based Products -
Recent Past, Current & Future Analysis by Product Segment for
Therapeutics (Cancer and Others), and Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years 2003 through
2010 (includes corresponding Graph/Chart)
- Table 61: Rest of World (*) Market for Monoclonal Antibody Based
Products - Long-term Projections by Product Segment for Therapeutics (Cancer
and Others), and Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 62: Rest of World 10-Year Perspective for Monoclonal Antibody
Based Products by Segment - Percentage Breakdown of Dollar Sales for
Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008
& 2012 (includes corresponding Graph/Chart)
COMPETITIVE LANDSCAPE
|
 |
